DelveInsight’s, “Lennox-Gastaut Syndrome Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Lennox-Gastaut Syndrome pipeline landscape. It covers the Lennox Gastaut Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Lennox Gastaut Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Lennox Gastaut Syndrome Pipeline Report

• DelveInsight’s Lennox Gastaut Syndrome pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Lennox Gastaut Syndrome treatment.
• The leading companies working in the Lennox Gastaut Syndrome Market include Takeda, Marinus Pharmaceuticals, SK Biopharmaceuticals, CuroNZ, TAHO Pharmaceuticals, Axium Pharmaceuticals, and others.
• Promising Lennox Gastaut Syndrome Pipeline Therapies in the various stages of development include ZX008 (Fenfluramine Hydrochloride), Carisbamate, ZX008 0.2 or 0.8 mg/kg/day, Clobazam, and others.
• November 2023: Jazz Pharmaceuticals announced a study of Phase 4 clinical trials for Cannabidiol. This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
• October 2023: Takeda announced a study of Phase 3 clinical trials for Soticlestat. Participants will receive their standard antiseizure therapy, plus either tablets of soticlestat or placebo. A placebo looks just like soticlestat but will not have any medicine in it. Participants will take soticlestat or placebo for 16 weeks, followed by a gradual dose reduction for 1 week. Then, participants will be followed up for 2 weeks.

 

Request a sample and discover the recent advances in Lennox Gastaut Syndrome Treatment Drugs @ Lennox Gastaut Syndrome Pipeline Report

 

In the Lennox Gastaut Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lennox-Gastaut Syndrome (LGS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Lennox Gastaut Syndrome Overview

Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Children with Lennox-Gastaut syndrome may also develop cognitive dysfunction, delays in reaching developmental milestones and behavioral problems.

 

Find out more about Lennox Gastaut Syndrome Therapeutics Assessment @ Lennox Gastaut Syndrome Preclinical and Discovery Stage Products

 

Lennox Gastaut Syndrome Emerging Drugs Profile

• Soticlestat: Takeda

 

Lennox Gastaut Syndrome Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the Lennox-Gastaut Syndrome therapies. The Lennox-Gastaut Syndrome companies which have their Lennox-Gastaut Syndrome (LGS) drug candidates in the most advanced stage, i.e. Phase III include, Takeda.

 

DelveInsight’s Lennox Gastaut Syndrome pipeline report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Lennox-Gastaut Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

 

Lennox Gastaut Syndrome Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Learn more about the emerging Lennox Gastaut Syndrome Pipeline Therapies @ Lennox Gastaut Syndrome Clinical Trials Assessment

 

Scope of the Lennox Gastaut Syndrome Pipeline Report

• Coverage- Global
• Lennox Gastaut Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Lennox Gastaut Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Lennox Gastaut Syndrome Companies- Takeda, Marinus Pharmaceuticals, SK biopharmaceuticals, CuroNZ, TAHO Pharmaceuticals, Axium Pharmaceuticals, and others.
• Lennox Gastaut Syndrome Pipeline Therapies- ZX008 (Fenfluramine Hydrochloride), Carisbamate, ZX008 0.2 or 0.8 mg/kg/day, Clobazam, and others.

 

Dive deep into rich insights for new drugs for Lennox Gastaut Syndrome Treatment, Visit @ Lennox Gastaut Syndrome Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Lennox-Gastaut Syndrome (LGS): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Lennox-Gastaut Syndrome (LGS) – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Soticlestat: Takeda
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Lennox-Gastaut Syndrome (LGS) Key Companies
21. Lennox-Gastaut Syndrome (LGS) Key Products
22. Lennox-Gastaut Syndrome (LGS)- Unmet Needs
23. Lennox-Gastaut Syndrome (LGS)- Market Drivers and Barriers
24. Lennox-Gastaut Syndrome (LGS)- Future Perspectives and Conclusion
25. Lennox-Gastaut Syndrome (LGS) Analyst Views
26. Appendix

 

For further information on the Lennox Gastaut Syndrome Pipeline therapeutics, reach out to Lennox Gastaut Syndrome Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/lennox-gastaut-syndrome-market